Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
F. De Baets, S. Van Daele, P. Schelstraete, F. Haerynck, M. Vaneechoutte (Ghent, Belgium). Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance. Eur Respir J 2005; 26: Suppl. 49, 1628

Member's Comments

No comment yet.

Related content which might interest you: Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Pseudomonas aeruginosa infections Source: Respipedia Article Year: 2018 Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections Source: Eur Respir J 2012; 40: 227-238 Year: 2012 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012 Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics Source: Eur Respir J 2008; 32: 1583-1590 Year: 2008 Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis Source: Eur Respir J 2014; 43: 900-903 Year: 2014 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis Source: ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019 Year: 2019 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013